Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRS201 in Acute Ulcerative Colitis
NCT06420492Phase 2Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of BRS201 in ulcerative colitis (UC) (4 arms), sponsored by Brigham and Women's Hospital. Primary endpoint: Sulfur Metabolism at 4 weeks. Started Sep 2025; status: recruiting.
02
Drugs
BRS201
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06420492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06420492.